Modified vaccinia ankara – bavarian nordic live virus: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Modified vaccinia ankara – bavarian nordic live virus: clinical details
Prescribing considerations
- Use according to current official recommendations and confirm eligibility and exposure context.
- Defer during acute severe febrile illness or acute infection; minor illness or low-grade fever alone is not a reason to defer.
- Assess atopic dermatitis and immunocompromise because reactions may be more frequent and immune responses may be lower.
- Use outside the adult licence only under appropriate official guidance and governance.
- Have treatment and supervision available for anaphylaxis and precautions against injury from syncope.
- Record the product name and batch number.
Contraindications and cautions
- Hypersensitivity to the active substance or excipients
- Hypersensitivity to trace chicken protein, benzonase, gentamicin or ciprofloxacin
- Previous sudden life-threatening allergic reaction to this vaccine or one of its components
Monitoring
- Observe for immediate allergic or vasovagal reactions.
- Advise about expected reactions and when urgent assessment is required.
- Monitor people with atopic dermatitis for marked reactions or disease flare.
- Consider reduced immunogenicity with HIV or other causes of immunosuppression.
- Report suspected adverse reactions through the Yellow Card Scheme, including the batch number where available.
Clinical pharmacology
A live attenuated, replication-defective modified vaccinia Ankara vaccine. It induces humoral and cellular immune responses that cross-recognise related orthopoxviruses; conventional pharmacokinetic assessment is not applicable.
Formulation and product differences
- A light yellow to pale white, milky suspension in a single-use vial.
- Produced in chick-embryo cells and may contain trace chicken protein, benzonase, gentamicin and ciprofloxacin.
- Gently swirl and inspect before use; discard damaged, discoloured or particulate-containing vaccine.
- Do not mix with other medicinal products or refreeze after thawing.
- The licensed route is subcutaneous; official UK programmes may use intramuscular or intradermal administration under relevant protocols.
Modified vaccinia ankara – bavarian nordic live virus interactions
Formal interaction studies are limited. Tell the vaccinator about recent vaccines, medicines and immune treatments.
Other vaccines
Product information advises avoiding concomitant administration because it has not been studied, whereas current UK programme guidance permits co-administration when appropriate. Clinicians should follow the applicable official protocol.
Immunoglobulins, including vaccinia immune globulin
Concurrent administration has not been studied and should be avoided according to product information.
Immunosuppressive treatments
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.